id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-024786-f33eb1nf	van Rensburg, V	Current evidence for directed and supportive investigational therapies against COVID-19	2020-04-24		.txt	text/plain	4411	279	49	Multiple trials across the globe are currently underway to assess the efficacy of CQ for the treatment and prevention of COVID-19, but no published, peer-reviewed results are available at the time of writing. [33] The rationale for the use of lopinavir/ritonavir (LPV/r) in COVID-19 stems from its in vitro activity against SARS-CoV-1, [34] as well as from a retrospective, multicentre cohort study evaluating LPV/r as early treatment in SARS-CoV-1, which demonstrated decreased mortality and intubation rates. [50] At the time of writing, there were no published peer-reviewed trials or case studies evaluating favipiravir in COVID-19, and its use is not currently recommended outside of clinical trials. A systematic review of treatment options in SARS-CoV-1 infection included corticosteroids' effects on mortality, in vitro inhibition of SARS viral replication and acute respiratory distress syndrome. Drugs that purportedly inhibit SARS-CoV-2 replication (such as the investigational antivirals) or viral entry and replication (CQ and HCQ) may therefore be more effective when given earlier in the COVID-19 disease course.	./cache/cord-024786-f33eb1nf.txt	./txt/cord-024786-f33eb1nf.txt